Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Denmark
  4. Nasdaq Copenhagen
  5. Orphazyme A/S
  6. News
  7. Summary
    ORPHA   DK0060910917

ORPHAZYME A/S

(ORPHA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Orphazyme A/S Reports Earnings Results for the Half Year Ended June 30, 2021

08/31/2021 | 01:00am EDT

Orphazyme A/S announced earnings results for the half year ended June 30, 2021. For the half year, the company announced sales was DKK 13.152 million. Operating loss was DKK 465.698 million compared to DKK 245.555 million a year ago. Net loss was DKK 463.780 million compared to DKK 251.415 million a year ago. Basic loss per share from continuing operations was DKK 13.27 compared to DKK 9.77 a year ago.


© S&P Capital IQ 2021
All news about ORPHAZYME A/S
10/19Pharnext renforce son équipe de direction avec trois nominations clés pour poursuivre l..
DJ
10/19Pharnext strengthens its management team with three key appointments to support ongoing..
DJ
10/18European ADRs Move Lower in Monday Trading
MT
10/14European ADRs Climb Higher in Thursday Trading
MT
10/08European ADRs Move Higher in Friday Trading
MT
10/07ORPHAZYME A/S : Modified long-term share-based incentive program for 2021 (Form 6-K)
PU
10/07ORPHAZYME A/S : Modified long-term share-based incentive program for 2021
AQ
10/05ORPHAZYME A/S : provides regulatory and financial updates (Form 6-K)
PU
10/05ORPHAZYME A/S : Says European Review of Arimoclomol Underway; Raises 2021 Cash Position Ou..
MT
10/05ORPHAZYME A/S : provides regulatory and financial updates
AQ
More news
Analyst Recommendations on ORPHAZYME A/S
More recommendations
Financials
Sales 2021 24,4 M 3,81 M 3,81 M
Net income 2021 -634 M -99,2 M -99,2 M
Net cash 2021 122 M 19,1 M 19,1 M
P/E ratio 2021 -1,74x
Yield 2021 -
Capitalization 934 M 146 M 146 M
EV / Sales 2021 33,3x
EV / Sales 2022 29,3x
Nbr of Employees 180
Free-Float 98,6%
Chart ORPHAZYME A/S
Duration : Period :
Orphazyme A/S Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ORPHAZYME A/S
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 2
Last Close Price 26,68 DKK
Average target price 60,50 DKK
Spread / Average Target 127%
EPS Revisions
Managers and Directors
Christophe Bourdon Chief Executive Officer
Anders Fink Vadsholt Chief Financial Officer
Georges Gemayel Chairman
Thomas Kirkegaard Jensen Chief Scientific Officer
Claus Bornæs Senior Manager-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
ORPHAZYME A/S-60.24%146
GILEAD SCIENCES, INC.14.83%83 880
WUXI APPTEC CO., LTD.29.16%66 875
BIONTECH SE222.44%63 484
REGENERON PHARMACEUTICALS14.28%57 402
VERTEX PHARMACEUTICALS-21.55%48 101